Navigation Links
AMDL Announces Investor Relations Presentation Available on Website
Date:7/3/2008

TUSTIN, Calif., July 3 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a world leader in specialty pharmaceuticals headquartered in Tustin, Ca., with operations in Shenzhen, Jiangxi, and Jilin, China, announced today it has released its investor presentation which is available for viewing on the Company's website at http://www.amdl.com.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to up
'/>"/>

SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nabriva Therapeutics Announces Appointment of New CEO
2. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
3. Biopure Announces Private Equity Financing
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
7. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
8. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
9. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
10. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
11. China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy Development ... following statement on Facebook today regarding the global Ice ... specifically for ALS research: , “Who would have thought ... raise all this awareness and funding toward ALS research! ... of the entire ALS community, would like to express ...
(Date:8/26/2014)... 26, 2014  ViveBio, LLC a leading provider ... and transportation, announced today that it has signed ... (LPS) of Knoxville, Tennessee ... the United States . ViveST is ... temperature dried biological specimen transport systems.  The technology ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... 21 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... been accepted for presentation at the American,College of Cardiology ... Chicago, IL on March 29 - April 1, 2008., ... Activity in Isolated Rat Left Atrial,Appendage; Poster; Sunday, March ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the fourth quarter and year-end 2007,financial results ... Chief Executive Officer of the Company, will host the ... in a press release to be,issued prior to the ...
... PDL BioPharma Have Entered into an Agreement Under, Which Genmab ... ... Minnesota, USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February ... PDLI ) announced today that they have entered into an ...
Cached Biology Technology:CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 2CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Researchers are still fascinated by the idea of the ... them into cells with the capacity to differentiate into ... are still striving to understand how it happens. ... (CNIO), headed by researcher Ralph P. Schneider, from the ...
... A new study finds that utilities aren,t rewarded for ... to make energy efficiency as attractive as renewables. ... Environmental Law , examines key differences between energy ... assistant professor at Oregon State University, outlines ways to ...
... a private company focused on the development of targeted ... has entered into a license agreement with the Spanish ... rights to develop and commercialise several novel kinase inhibitors ... CNIO,s considerable expertise in drug discovery and comprise a ...
Cached Biology News:CNIO researchers identify a new gene that is essential for nuclear reprogramming 2Study finds disincentives to energy efficiency can be fixed 2